Intravenous administration of cilostazol nanoparticles ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced injury model

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 29329-29344

  Nagai, Noriaki ^a   Yoshioka, Chiaki ^a   Ito, Yoshimasa ^a   Funakami, Yoshinori ^a   Nishikawa, Hiroyuki ^a   Kawabata, Atsufumi ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Cilostazol; Injection formulation; Ischemic stroke; Nanoparticles; Pharmacokinetics

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CILOSTAZOL; NANOPARTICLE; NEUROPROTECTIVE AGENT; TETRAZOLE DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD PRESSURE MONITORING; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; MALE; MATHEMATICAL MODEL; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; REPERFUSION INJURY; ANIMAL; BLOOD PRESSURE; BRAIN; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; RABBITS AND HARES; VASCULARIZATION; WISTAR RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BLOOD PRESSURE; BRAIN; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE, INBRED ICR; NANOPARTICLES; NEUROPROTECTIVE AGENTS; RABBITS; RATS, WISTAR; REPERFUSION INJURY; TETRAZOLES;

EID: 84949818724     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226166     Document Type: Article

References (40)

1. Go, A.S. The epidemiology of atrial fibrillation in elderly persons: The tip of the iceberg. Am. J. Geriatr. Cardiol. 2005, 14, 56–61. [CrossRef] [PubMed]
2. Nito, C.; Kamada, H.; Endo, H.; Niizuma, K.; Myer, D.J.; Chan, P.H. Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab. 2008, 28, 1686–1696. [CrossRef] [PubMed]
3. Diaz-Ruiz, A.; Vacio-Adame, P.; Monroy-Noyola, A.; Méndez-Armenta, M.; Ortiz-Plata, A.; Montes, S.; Rios, C. Metallothionein-II inhibits lipid peroxidation and improves functional recovery after transient brain ischemia and reperfusion in rats. Oxid. Med. Cell. Longev. 2014. [CrossRef] [PubMed]
4. Castillo, J.; Dávalos, A.; Noya, M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997, 349, 79–83. [CrossRef]
5. Cuzzocrea, S.; Riley, D.P.; Caputi, A.P.; Salvemini, D. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 2001, 53, 135–159. [PubMed]
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333, 1581–1587
7. Ishiguro, M.; Mishiro, K.; Fujiwara, Y.; Chen, H.; Izuta, H.; Tsuruma, K.; Shimazawa, M.; Yoshimura, S.; Satoh, M.; Iwama, T., et al. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS ONE 2010, 5, 15178. [CrossRef] [PubMed]
8. Liu, Y.; Shakur, Y.; Yoshitake, M.; Kambayashi, J.-I. Cilostazol (pletalr): Adual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev. 2001, 19, 369–386. [CrossRef] [PubMed]
9. Kim, K.Y.; Shin, H.K.; Choi, J.M.; Hong, K.W. Inhibition of lipopolysaccharide induced apoptosis by cilostazol in human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 2002, 300, 709–715. [CrossRef] [PubMed]
10. Fujita, Y.; Lin, J.X.; Takahashi, R.; Tomimoto, H. Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. Brain Res. 2008, 1203, 170–176. [CrossRef] [PubMed]
11. Tanaka, K.; Gotoh, F.; Fukuuchi, Y.; Amano, T.; Uematsu, D.; Kawamura, J.; Yamawaki, T.; Itoh, N.; Obara, K.; Muramatsu, K. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989, 20, 668–673. [CrossRef] [PubMed]
12. Oyama, N.; Yagita, Y.; Kawamura, M.; Sugiyama, Y.; Terasaki, Y.; Omura-Matsuoka, E.; Sasaki, T.; Kitagawa, K. Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 2011, 42, 2571–2577. [CrossRef] [PubMed]
13. Kasahara, Y.; Nakagomi, T.; Matsuyama, T.; Stern, D.; Taguchi, A. Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke 2012, 43, 499–506. [CrossRef] [PubMed]
14. Nonaka, Y.; Tsuruma, K.; Shimazawa, M.; Yoshimura, S.; Iwama, T.; Hara, H. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci. Lett. 2009, 452, 156–161. [CrossRef] [PubMed]
15. Ishida, T.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes after repeated injection. Drug Deliv. Syst. 2004, 19, 495–510. [CrossRef]
16. Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug delivery design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47, 113–131. [CrossRef]
17. Igarashi, R.; Takenaga, M.; Takeuchi, J.; Kitagawa, A.; Matsumoto, K.; Mizushima, Y. Marked hypotensive and blood flow-increasing effects of a newlipo-PGE1 (lipo-AS013) due to vascular wall targeting. J. Control. Release 2001, 71, 157–164. [CrossRef]
18. Murakami, H.; Kobayashi, M.; Takeuchi, H.; Kawashima, Y. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. Powder Technol. 2000, 107, 137–143. [CrossRef]
19. Kawashima, Y. Design of poly(lactic-co-glycolic acid) (PLGA) nanosphere for developing to DDS. J. Pharm. Sci. Technol. Jpn. 2006, 66, 224–238
20. Tsukada, Y.; Hara, K.; Bando, Y.; Huang, C.C.; Kousaka, Y.; Kawashima, Y.; Morishita, R.; Tsujimoto, H. Particle size control of poly(D,L-lactide-co-glycolide) nanospheres for sterile applications. Int. J. Pharm. 2009, 370, 196–201. [CrossRef] [PubMed]
21. Nagai, N.; Ito, Y.; Okamoto, N.; Shimomura, Y. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 2014, 319, 53–62. [CrossRef] [PubMed]
22. Nagai, N.; Yoshioka, C.; Mano, Y.; Tanabe, W.; Ito, Y.; Okamoto, N.; Shimomura, Y. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure. Exp. Eye Res. 2015, 132, 115–123. [CrossRef] [PubMed]
23. Carmichael, S.T. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005, 2, 396–409. [CrossRef] [PubMed]
24. Wells, M.R.; Kraus, K.; Batter, D.K.; Blunt, D.G.; Weremowitz, J.; Lynch, S.E.; Antoniades, H.N.; Hansson, H.A. Gel matrix vehicles for growth factor application in nerve gap injuries repaired with tubes: A comparison of biomatrix, collagen, and methylcellulose. Exp. Neurol. 1997, 146, 395–402. [CrossRef] [PubMed]
25. Gupta, D.; Tator, C.H.; Shoichet, M.S. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006, 27, 2370–2379. [CrossRef] [PubMed]
26. Chouly, C.; Pouliquen, D.; Lucet, I.; Jeune, J.J.; Jallet, P. Development of superparamagnetic nanoparticles for MRI: Effect of particle size, charge and surface nature on biodistribution. J. Microencapsul. 1996, 13, 245–255. [CrossRef] [PubMed]
27. Begley, D.J. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol. Ther. 2004, 104, 29–45. [CrossRef] [PubMed]
28. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5, 487–495. [CrossRef] [PubMed]
29. Toy, R.; Peiris, P.M.; Ghaghada, K.B.; Karathanasis, E. Shaping cancer nanomedicine: The effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine 2014, 9, 121–134. [CrossRef] [PubMed]
30. Kimura, Y.; Tani, T.; Kanbe, T.; Watanabe, K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim. Forsch. 1985, 35, 1144–1149
31. Minami, N.; Suzuki, Y.; Yamamoto, M.; Kihira, H.; Imai, E.; Wada, H.; Kimura, Y.; Ikeda, Y.; Shiku, H.; Nishikawa, M. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997, 61, 383–389. [CrossRef]
32. Kohda, N.; Tani, T.; Nakayama, S.; Adachi, T.; Marukawa, K.; Ito, R.; Ishida, K.; Matsumoto, Y.; Kimura, Y. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb. Res. 1999, 96, 261–268. [CrossRef]
33. Kawamura, K.; Watanabe, K.; Kimura, Y. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneim. Forsch. 1985, 35, 1149–1154
34. Lee, J.H.; Park, S.Y.; Lee, W.S.; Hong, K.W. Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. Neurol. Res. 2005, 27, 483–492. [CrossRef] [PubMed]
35. Lee, J.H.; Kim, K.Y.; Lee, Y.K.; Park, S.Y.; Kim, C.D.; Lee, W.S.; Rhim, B.Y.; Hong, K.W. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J. Pharmacol. Exp. Ther. 2004, 308, 896–903. [CrossRef] [PubMed]
36. Lee, J.H.; Park, S.Y.; Shin, H.K.; Kim, C.D.; Lee, W.S.; Hong, K.W. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci. Ther. 2008, 14, 143–152. [CrossRef] [PubMed]
37. Wakida, K.; Morimoto, N.; Shimazawa, M.; Hozumi, I.; Nagase, H.; Inuzuka, T.; Hara, H. Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2. Brain Res. 2006, 1116, 187–193. [CrossRef] [PubMed]
38. Okamoto, N.; Ito, Y.; Nagai, N.; Murao, T.; Takiguchi, Y.; Kurimoto, T.; Mimura, O. Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea. J. Oleo Sci. 2010, 59, 423–430. [CrossRef] [PubMed]
39. Hara, H.; Huang, P.L.; Panahian, N.; Fishman, M.C.; Moskowitz, M.A. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transientMCAocclusion. J. Cereb. Blood Flow Metab. 1996, 16, 605–611. [CrossRef] [PubMed]
40. Funakami, Y.; Hata, T.; Itoh, E.; Itano, S. Effects of some β-adrenoceptor antagonists on orthostatic hypotension in repeatedly cold- (SART-) stressed rats. Biol. Pharm. Bull. 2007, 30, 303–308. [CrossRef] [PubMed]